Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Patient Story: CAR-T Therapy Brings New Hope for Lymphoma Patients – A Case from a Chinese Hospital
**Patient Story: CAR-T Therapy Brings New Hope for Lymphoma Patients – A Case from a Chinese Hospital**
Patient Story
In the field of cancer treatment, China has achieved groundbreaking success with CAR-T cell therapy, especially in treating relapsed or refractory lymphoma. Today, we share the story of one patient whose life was transformed through this revolutionary treatment provided by a leading hospital in China.
## Patient Journey: Diagnosed with Complex Lymphoma
Mr. Li, a 59-year-old man from China with a long history of hypertension, noticed swelling in his right elbow in September 2019. As the swelling worsened over the following months, he sensed that something was seriously wrong. After evaluations at multiple hospitals, he was diagnosed with diffuse large B-cell lymphoma (DLBCL). Complicating matters, genetic testing revealed that he had TP53 and MYD88 mutations, making his case particularly challenging.
At a local hospital, Mr. Li underwent a series of standard treatments, including cyclophosphamide, prednisone, ibrutinib, and rituximab. Initially, his condition improved, but six months later, he began experiencing discomfort in his lower abdomen. Testing confirmed that his lymphoma had relapsed and spread. Multiple rounds of second-line, third-line, and even fourth-line treatments were unable to control his disease.
## Last Hope: China’s CAR-T Therapy Shows Remarkable Effect
With few options left, Mr. Li reached out to our Advanced Medicine in China team as his last hope. Our expert team took on his case, and he was promptly admitted to begin CAR-T cell therapy in China. This innovative treatment involves reprogramming the patient’s own immune cells to recognize and attack cancer cells. Chinese experts created a precise treatment plan for Mr. Li and initiated CAR-T cell infusion.
The treatment response was remarkable. Although Mr. Li experienced a brief period of fever and mild neutropenia following therapy, these symptoms resolved quickly with supportive care. He avoided severe side effects often associated with CAR-T therapy, such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). A month later, his follow-up scan revealed complete remission (CR). The Chinese CAR-T treatment not only successfully controlled his high-risk lymphoma but also spared him many of the common side effects.
## Expert Insights: A New Option for High-Risk Patients
This case demonstrates the significant effectiveness of China’s CAR-T therapy for patients with high-risk genetic mutations. Our team’s expert professor noted that patients with TP53 mutations, like Mr. Li, often respond poorly to standard first-line treatments but may achieve substantial improvement through CAR-T therapy. For high-risk patients such as Mr. Li, especially those with dual-expression and relapse within 12 months, early CAR-T treatment could yield greater benefits. CAR-T therapy in China may result in prolonged bone marrow suppression, which requires careful monitoring and supportive care based on the patient’s prior chemotherapy history and individual response.
China’s CAR-T therapy is bringing new hope for lymphoma patients around the world. It not only paves a new path in treatment options but also broadens our understanding of lymphoma treatment. By giving patients renewed hope for recovery, we look forward to this technology enabling lasting remission for even more lymphoma patients and offering a brighter future ahead.
🎉🎉To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#CancerTreatment #RRLymphoma #ChineseMedicalAdvances #Immunotherapy #PatientSuccess #Oncology #HopeForCancer #MedicalBreakthrough #CancerResearch #China
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Exceptional Efficacy of CAR-T Therapy in China: Disease Control Rate for Advanced Liver Cancer Reaches 78% to 91.3%
### Exceptional Efficacy of CAR-T Therapy in China: Disease Control Rate for Advanced Liver Cancer Reaches 78% to 91.3%
Liver Cancer
#CARTTherapy #LiverCancer #SolidTumors
In recent years, China has made remarkable advances in CAR-T cell therapy, particularly demonstrating exceptional potential in liver cancer treatment. CAR-T cell therapy, or chimeric antigen receptor T-cell therapy, involves genetically engineering a patient’s T-cells to enable precise recognition and elimination of cancer cells. This innovative therapy has shown impressive outcomes in treating hematologic cancers and is now showing promising potential in fighting more complex solid tumors—especially liver cancer.
### **A Ray of Hope with CAR-T Therapy Amid High Incidence of Liver Cancer**
Liver cancer ranks among the top three cancers worldwide and poses a significant health threat. The high incidence of liver cancer, largely related to chronic hepatitis B infection, is particularly evident in China, which accounts for 42.4% of global liver cancer cases, with an annual increase of 368,000 new cases. For many liver cancer patients, especially those with advanced-stage disease, traditional treatments offer limited effectiveness. CAR-T therapy, however, provides new hope. Recent studies indicate that the disease control rate of CAR-T therapy for advanced liver cancer patients in China has reached an impressive 78% to 91.3%, showcasing its powerful treatment potential.
### **Patient Stories: CAR-T Therapy as a Turning Point in Life**
One inspiring case is that of Mr. Zhang from China. Long troubled by chronic hepatitis, he was diagnosed with advanced liver cancer in 2016. Despite undergoing liver resection, the cancer recurred with multiple intrahepatic metastases, spreading to retroperitoneal lymph nodes and forming a tumor thrombus in the inferior vena cava. After multiple rounds of embolization and ablation, the tumor remained uncontrolled. Given the limited efficacy of traditional treatments, doctors recommended CAR-T therapy. Following CAR-T treatment, Mr. Zhang’s tumors completely disappeared, and he has remained tumor-free for over seven years without severe side effects. This case highlights both the efficacy of CAR-T therapy and its potential to offer hope.
Another patient, Mr. Li, also benefitted from CAR-T therapy. When other treatments proved ineffective, doctors developed a liver cancer-specific CAR-T “special force” of four billion cells for him. Upon injection of these modified CAR-T cells, Mr. Li’s alpha-fetoprotein levels dropped rapidly, and the tumor gradually shrank. In subsequent treatments, Mr. Li’s tumor disappeared entirely, and his condition has remained stable long-term. This success story further underscores CAR-T therapy’s impressive results in treating liver cancer.
### **Future Outlook: Challenges and Opportunities for CAR-T Therapy in China**
While CAR-T therapy has achieved notable successes, challenges remain. Compared to hematologic cancers, the environment for treating solid tumors is more complex, and enhancing the efficacy of CAR-T cells in solid tumors requires ongoing optimization. However, the promising research and clinical results instill confidence in CAR-T therapy’s future in liver cancer treatment. Chinese researchers are actively working to refine CAR-T cell therapy, explore combination treatment strategies, and foster international collaboration to benefit more patients.
In the future, CAR-T therapy in China is expected to become a powerful tool in liver cancer treatment, offering new hope to thousands of patients. With ongoing technological advancements and deepening clinical practice, CAR-T therapy in China will continue to advance cancer immunotherapy and provide new possibilities for the health of liver cancer patients.
🎉🎉To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#CancerTreatment #ChinaMedicalAdvances #CancerImmunotherapy #MedicalBreakthrough #CancerResearch #LiverCancerAwareness #AdvancedCancerTreatment #CancerSurvivors #BiotechInnovation #GeneTherapy #Oncology #MedicalInnovation
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
New Advances in Chinese CAR-T Cell Therapy: CD27 Armored BCMA CAR-T Shows Potential in Treating Relapsed Multiple Myeloma
**New Advances in Chinese CAR-T Cell Therapy: CD27 Armored BCMA CAR-T Shows Potential in Treating Relapsed Multiple Myeloma**
Multiple Myeloma
#BCMA #CD27#CARTCellTherapy #RRMM #MM #MultipleMyeloma #CART
Relapsed and refractory multiple myeloma (RRMM) is a challenging blood cancer that poses significant obstacles for patients. Although several BCMA (B-cell maturation antigen) targeting CAR-T cell therapies have been developed, achieving long-term remission and extended survival remains difficult. The recent introduction of CD27-armored BCMA CAR-T—CBG-002—by a Chinese medical team brings new hope for RRMM patients. Based on preclinical data, this therapy shows promising anti-myeloma activity, with Phase I clinical trial results further validating its efficacy and safety.
Research Highlights
CBG-002 is an innovative therapy that enhances traditional BCMA CAR-T by adding a CD27 costimulatory domain. The inclusion of CD27 improves CAR-T cell persistence and activity, contributing to stronger anti-cancer effects. Recently published Phase I research in Cancer Immunology Research indicates that this CD27-armored BCMA CAR-T therapy is not only well-tolerated but also shows notable efficacy in RRMM patients.
The study enrolled 11 RRMM patients, all of whom had undergone three or more prior treatments, with a median age of 54. The results showed that 81.8% of patients experienced only mild cytokine release syndrome (CRS) and no severe neurotoxicity. Even at a low dosage level (1-3×10^6 CAR-T cells/kg), CBG-002 achieved a high overall response rate (ORR) of 81.8%, with 45.5% of patients reaching stringent complete remission.
Future Outlook
The Phase I study of CBG-002 not only confirmed its efficacy but also demonstrated advantages in production time and cost. Compared to current products on the market, CBG-002 has a shortened production cycle of just 10 days, making it a timely and affordable treatment option for more patients. Amid global progress in CAR-T cell therapies, the innovation by this Chinese medical team positions it as a significant force in advancing cancer research worldwide.
🎉🎉To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#MultipleMyeloma #CancerResearch #Immunotherapy #ChinaBiotech #Oncology
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
China Overcomes Solid Tumor Challenge: CAR-T Technology IM96 Leads Innovation in Colorectal Cancer Treatment
**China Overcomes Solid Tumor Challenge: CAR-T Technology IM96 Leads Innovation in Colorectal Cancer Treatment**
Colorectal Cancer
#IM96 #CART #ColorectalCancer #CARTtherapy #ESMO #2024ASCO #SolidTumor
China has made remarkable progress in the field of innovative cancer treatment. In October 2024, a Chinese biotechnology company announced that IM96 CAR-T cell injection, developed in collaboration with Peking University Cancer Hospital, received clinical trial approval from the National Medical Products Administration (NMPA). This marks a significant milestone for China in applying CAR-T technology to solid tumor treatment. IM96 is the first CAR-T cell drug approved in China for the treatment of metastatic colorectal cancer and has become the sixth CAR-T product approved for this company.
### Breakthroughs in IM96 Technology and Clinical Trial Highlights
IM96 utilizes ActSep-CD3/CD28 sorting and activation magnetic beads from China’s National Biopharmaceutical Technology Innovation Center. This is a cutting-edge technology, marking the first time China’s GMP-grade micron magnetic beads have been used in a CAR-T cell drug clinical trial, laying an important foundation for improved efficacy and safety.
The clinical trial of IM96 is led by Peking University Cancer Hospital, with Professor Lin Shen, a renowned oncology expert, as the principal investigator. Its preclinical study data has gained international recognition and was selected for the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, attracting significant attention.
### Exceptional Efficacy and Safety
IM96 has demonstrated outstanding efficacy in preclinical studies. Data shows a Disease Control Rate (DCR) of 73.7%, an Objective Response Rate (ORR) of 50%, and a median Progression-Free Survival (mPFS) exceeding 10 months. These results indicate a strong potential for IM96 in controlling tumor progression in metastatic colorectal cancer.
Additionally, IM96’s safety has been well-validated in preclinical studies, with only 5.0% of patients experiencing neurotoxicity or severe Cytokine Release Syndrome (CRS), underscoring its advantage in managing side effects.
### Meeting the Urgent Need for Metastatic Colorectal Cancer Treatment
Colorectal cancer is the third most prevalent cancer worldwide, with 1.93 million new cases and over 930,000 deaths each year. In China, the incidence and mortality rates of this cancer are high, particularly among advanced-stage metastatic patients who have limited treatment options. As an innovative solid tumor CAR-T drug developed independently in China, IM96 will address the gap in CAR-T therapies for colorectal cancer, offering new hope for patients.
### International Recognition and Academic Achievements
IM96 has been selected for consecutive presentations at the 2023 European Society for Medical Oncology (ESMO) and the 2024 ASCO Annual Meeting. Its excellent preclinical data has garnered global attention in the oncology community. The research findings have been accepted for publication in the prestigious *Journal for ImmunoTherapy of Cancer*. These achievements not only highlight China’s strength in CAR-T innovation but also contribute new perspectives and strategies to global cancer treatment.
The approval of IM96 marks a new phase in China’s development of CAR-T therapies, especially for solid tumors, and is expected to provide more effective and safer treatment options for colorectal cancer patients worldwide. This breakthrough will further enhance China’s international standing in cancer treatment and inject new momentum into global advancements in anti-cancer technologies.
🎉🎉To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#CancerTreatment #MedicalInnovation #ChinaBiotech #Oncology
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
CAR-T Cell Therapy as a New Option for Treating Multiple Myeloma
**CAR-T Cell Therapy as a New Option for Treating Multiple Myeloma**
Multiple Myeloma
“CAR-T cell therapy has now become a new option for treating patients with relapsed and refractory multiple myeloma, with hopes of changing the difficult situation in myeloma treatment where treatments are either ineffective or unavailable,” said Jin Jie, Director of the Hematology Department at the First Affiliated Hospital of Zhejiang University School of Medicine, in an interview with People’s Daily Health on October 23.
Early on October 23, Jin Jie visited the hospital ward to see a 72-year-old patient with multiple myeloma. Just the day before, the patient had begun receiving treatment with a domestically produced BCMA-targeting CAR-T drug.
“This 72-year-old patient came to the hospital due to bone pain and was even unable to walk steadily,” Jin recalled. After being diagnosed with multiple myeloma, the patient initially received a series of chemotherapy regimens that showed some efficacy. However, a year after undergoing autologous hematopoietic stem cell transplantation, the disease relapsed, and various subsequent treatments proved suboptimal. As a result, the patient opted for CAR-T therapy.
Since the approval of Equecabtagene Autoleucel last year, Professor Jin Jie became one of the first doctors nationwide to prescribe CAR-T drugs for multiple myeloma. This patient is her tenth multiple myeloma patient to receive this innovative therapy. Discussing the treatment outcomes, Jin noted, “The overall efficacy for patients has been very good.” A month ago, another patient who underwent this CAR-T therapy returned for a follow-up. “Everything was going well; we will continue to monitor the patient’s indicators until all data are stable.”
Multiple myeloma is a malignant plasma cell disease that predominantly affects older adults. Jin observed that the incidence of multiple myeloma has been trending younger in recent years, with patients in their forties commonly seen in clinical settings. Currently, multiple myeloma remains an incurable disease, and most patients face inevitable relapse. However, thanks to the emergence of new drugs and advances in treatment, both the efficacy and overall survival of patients have significantly improved in recent years.
“CAR-T therapy involves collecting a patient’s T cells and equipping them with a ‘weapon.’ These T cells are then expanded outside the body and re-infused into the patient, where they target and attack tumor cells, while also being able to proliferate in the patient’s body to eliminate cancer cells,” Jin explained. CAR-T therapy has the potential to give patients a higher quality of life.
CAR-T cell therapy has been advancing rapidly in the field of multiple myeloma, with multiple products already approved and available. In Jin’s view, patients should, under professional guidance, choose drugs and treatments with extensive clinical experience and proven efficacy.
🎉🎉To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
**#MultipleMyeloma #CAR_TCellTherapy #CancerTreatment #Immunotherapy #Hematology #CellTherapy #MedicalInnovation #PatientCare #Oncology #ZhejiangUniversity**
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
China’s CAR-T Therapy: A Beacon of Hope for Children with Acute Lymphoblastic Leukemia (ALL)
China’s CAR-T Therapy: A Beacon of Hope for Children with Acute Lymphoblastic Leukemia (ALL)
#CARTTherapy #Leukemia #ChildhoodCancer #ALL #CART #AcuteLymphoblasticLeukemia #Patientstory
China’s CAR-T cell therapy is emerging as a beacon of hope in the fight against cancer, bringing unprecedented treatment possibilities. As a precise cellular immunotherapy, CAR-T therapy enhances the cancer-fighting abilities of T-cells through genetic editing technology, offering breakthroughs for patients with cancers resistant to traditional treatments, especially in blood cancers like leukemia.
From Diagnosis to Treatment: Strength and Struggle
Shan is a young child in China who has endured long-term treatment for leukemia. Diagnosed with acute lymphoblastic leukemia (ALL) in 2019, this news brought immense suffering to her and her family, as she was only five years old. Although ALL generally responds well to chemotherapy, Shan’s cancer cells persisted stubbornly after several rounds of chemotherapy, failing to reach full remission. Her doctors recommended a bone marrow transplant, but due to physical and family constraints, she had to opt for conservative treatment. Nevertheless, Shan did not give up her desire to live, showing remarkable resilience over five years.
A New Hope Through CAR-T Therapy
In 2023, Shan’s condition worsened as her anemia grew severe, with her hemoglobin levels dropping to a critical point. Faced with despair, her mother reached out to our team at Advanced Medicine in China, where experts quickly admitted her to the hospital. After a comprehensive evaluation, our hematology-oncology specialists decided to proceed with CAR-T therapy for her.
Following a thorough process of gene modification and the infusion of CAR-T cells, Shan’s condition improved rapidly. In the early stages of treatment, her complexion brightened, her energy levels noticeably improved, and subsequent tests showed that her tumor cells had completely disappeared, achieving clinical remission. Shan was finally free from the shadow of cancer, gradually regaining the joy and health of childhood.
A Medical Breakthrough: New Hope for Children with Leukemia
Shan’s success story signifies the maturation of CAR-T therapy in China, showcasing its powerful potential, particularly in treating refractory and relapsed childhood acute leukemia. In recent years, Chinese medical teams have actively adopted CAR-T technology in treating pediatric blood cancers, achieving remarkable long-term remission for many children. As the country with the highest number of CAR-T therapy applications globally, China’s hospital teams possess extensive experience and advanced technological capabilities, offering high-quality treatment to more children suffering from relapsed and refractory blood diseases.
Moving Forward: A Promising Future for Cellular Immunotherapy
With the continued development of CAR-T therapy in China, more patients with challenging cancers stand to benefit. Shan’s recovery is not only a family’s joy but also a testament to China’s medical progress. CAR-T therapy is ushering in a new era of cellular immunotherapy, giving more patients the possibility of life extension and recovery.
🎉🎉To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: Https://wa.me/+861371795907
Email: doctor.huang@globecancer.com
#CancerResearch #MedicalBreakthrough #Immunotherapy #ChinaMedicine #Oncology #CancerHope #LeukemiaAwareness #CancerTreatment
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Chinese Scientists Achieve Major Breakthrough in Enhancing CAR-T Cell Efficacy: MEK Inhibitors Effectively Prevent CAR-T Cell Exhaustion
Chinese Scientists Achieve Major Breakthrough in Enhancing CAR-T Cell Efficacy: MEK Inhibitors Effectively Prevent CAR-T Cell Exhaustion
CAR-T
#CARTCellTherapy #MEKInhibitors #CancerResearch #ChineseScientists #CART #MEK
In recent years, CAR-T cell therapy has shown remarkable effectiveness in treating relapsed or refractory B-cell malignancies, particularly in cases where targeted therapies have failed. However, CAR-T therapy’s long-term effectiveness is often limited due to T-cell exhaustion and terminal differentiation, especially for patients with hematological malignancies and solid tumors. Extending the efficacy of CAR-T cells has been a global challenge in the scientific community.
On October 22, 2024, a team of Chinese medical researchers published a groundbreaking study in the prestigious journal *Signal Transduction and Targeted Therapy*, titled “MEK inhibition prevents CAR-T cell exhaustion and differentiation via downregulation of c-Fos and JunB.” This study reveals a new strategy to enhance the efficacy of CAR-T cells by using MEK inhibitors. The research demonstrates that MEK inhibitors (MEKi) can significantly reduce CAR-T cell exhaustion and terminal differentiation by suppressing the expression of c-Fos and JunB. This discovery provides a new approach to improving CAR-T therapy, especially in the context of combined treatments for both hematological malignancies and solid tumors.
MEK1/2 inhibitors have already been widely used in treating tumors with RAS or RAF mutations, playing a crucial role in cancer therapy through immune modulation. The Chinese research team further confirmed that MEKi can effectively reduce the excessive activation and exhaustion of CAR-T cells, extending their persistence and anti-tumor activity in vivo. This study not only highlights the positive impact of MEKi on CAR-T therapy but also lays the groundwork for future combination treatments to further enhance therapeutic efficacy.
The team’s research underscores the importance of the MAPK signaling pathway, particularly the roles of c-Fos and JunB in CAR-T cell function. By inhibiting the expression of these two transcription factors, the researchers successfully prevented premature exhaustion and terminal differentiation in CAR-T cells, maintaining their higher efficacy in fighting tumors.
This discovery expands the potential applications of MEKi in improving CAR-T therapy, especially through combined treatment strategies that promise to significantly improve outcomes for cancer patients. This groundbreaking study not only marks another important contribution from Chinese scientists in the field of CAR-T therapy but also opens new avenues for global cancer treatment.
Through this research, the Chinese medical research team has provided new hope for the clinical application of CAR-T therapy, revealing the potential for multiple combination treatment strategies and bringing more possibilities in the fight against cancer.
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of Advanced Medicine in China for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#CancerBreakthrough #Immunotherapy #TargetedTherapy #TCellExhaustion #CARTInnovation #CancerTreatment #MedicalResearch #Oncology #Biotechnology
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Recommended Myeloma Expert – Professor Qiu Luguo – A Leading Specialist in Hematology and Multiple Myeloma
### Recommended Myeloma Expert – Professor Qiu Luguo – A Leading Specialist in Hematology and Multiple Myeloma
Expert
We at Advanced Medicine In China are proud to have Professor Qiu Luguo as our contracted expert. He provides telemedicine consultations for our international patients and can arrange for them to travel to China through a special fast-track system. Patients can receive treatment in the hospital where Professor Qiu works, under his direct supervision as their attending physician, ensuring comprehensive and professional care throughout the treatment process.
Professor Qiu is renowned in the field of hematologic oncology, particularly for treating patients who have not responded well to standard therapies. His deep expertise and innovative treatment approaches have brought new hope to patients, especially those with complex conditions. Through our services, international patients can not only access cutting-edge treatment recommendations via telemedicine but also come to China to receive the most advanced medical care.
The process is straightforward and efficient. Patients only need to submit the following documents, and our team will assist in arranging everything from teleconsultation to full treatment in China:
-
Pathology report
-
Latest discharge summary
-
Detailed description of the condition
-
History of treatment and its effectiveness
We recommend Professor Qiu for his exceptional achievements and extensive experience, which have provided a wide range of treatment options for countless hematologic cancer patients. His international reputation further affirms his outstanding contributions to the fields of hematology and multiple myeloma.
### Expert Profile
Professor Qiu Luguo is the Director of the Lymphoma Diagnosis and Treatment Center at the Hematology Hospital, Chinese Academy of Medical Sciences, and Director of the Tianjin Cord Blood Hematopoietic Stem Cell Bank. He has long been dedicated to both clinical and basic research in hematologic diseases. Professor Qiu is a recipient of the State Council’s special government allowance and has been recognized as an Outstanding Young and Middle-aged Expert by the National Health Commission of China. As a leading authority in lymphoma and multiple myeloma treatment, he is also a member of several international academic organizations, including the International Myeloma Society (IMS) and the International Myeloma Working Group (IMWG).
### Areas of Expertise
Professor Qiu is highly skilled in the diagnosis and treatment of lymphatic system tumors, particularly in the precise diagnosis, stratified treatment, and prognosis evaluation of lymphoma, chronic lymphocytic leukemia, and multiple myeloma. He has also made significant progress in the application of hematopoietic stem cell transplantation technology, offering new treatment options for patients with hematologic diseases.
### Research Contributions and International Recognition
Throughout his 30-plus-year career, Professor Qiu has completed more than 30 national research projects and published nearly 700 papers in leading academic journals, with over 160 of them in SCI-indexed journals. His research achievements have garnered widespread attention in China and have been highly regarded in the international hematology community. He has been invited to speak at numerous international conferences and actively promotes global academic collaboration and exchange.
### Major Research Directions
Professor Qiu’s research focuses on the pathogenesis and precision treatment strategies for lymphatic system tumors. His work spans a broad range of fields, from basic research to clinical applications, covering the diagnosis, prognosis, and personalized treatment of lymphoma, multiple myeloma, and chronic lymphocytic leukemia. Additionally, he has conducted in-depth studies on hematopoietic stem cell transplantation and stem cell engineering, striving to develop innovative therapies that improve patient cure rates.
### Publications and Scientific Achievements
Professor Qiu has authored five major medical books, holds five national invention patents, and has received multiple first-place awards for his scientific achievements in China. His groundbreaking work in the genomics of multiple myeloma and chronic lymphocytic leukemia has made significant progress in early diagnosis and targeted treatment of these diseases. His research has not only advanced the treatment of lymphatic system tumors but also set an example for young researchers in the field of hematology.
With his exceptional clinical and research accomplishments, Professor Qiu Luguo has become a key figure in the global hematology community. His contributions have not only brought hope to patients but also laid a solid foundation for future advancements in the treatment of blood diseases. Some of his major publications include:…
-
Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. J Clin Invest. 2022 Feb 1;132(3):e153283. (IF: 19.456)
-
Indirubin-3′-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma. E Bio Medicine. 2022 Apr;78:103950. (IF:11.205)
-
A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia. Clin Cancer Res. 2021 Oct 15;27(20):5492-5501. (IF: 12.531)
-
A Phase I Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2021 May 27;137(21):2890-2901. (IF: 22.133)
-
High incidence of MYD88 and KMT2D mutations in Chinese with chronic lymphocytic leukemia. Leukemia. 2021 Aug;35(8):2412-2415. Jan 22. (IF:12.883)
-
YWHAE/14-3-3ε expression impacts the protein load contributing to proteasome inhibitor sensitivity in multiple myeloma. Blood. 2020，136(4):468-479. (IF:16.509)
-
Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma. Leukemia. 2020,34(2):578-588. (IF:11.528)
-
Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma. J Clin Invest. 2018,128(7):2877-2893. (IF:12.87)
-
Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma. Leukemia. 2017.31(5):123-1135. (IF:11.412)
-
Intratumoral genetic heterogeneity and number of cytogenetic aberrations provide additional prognostic significance in chronic lymphocytic leukemia. Genet Med.19(2):182-191. (IF:7.756)
### Online Consultation and Appointment Information
Professor Ke currently offers online video consultation services. Patients can make appointments through the following methods:
WhatsApp: Https://wa.me/+8613717959070
Wechat：doctors0152
Email: doctor.huang@globecancer.com
#HematologyExpert #MultipleMyeloma #LymphomaTreatment #BloodCancer #StemCellTransplantation #MedicalInnovation #Telemedicine #InternationalHealthcare #AdvancedMedicineInChina #PrecisionMedicine #ProfessorQiuLuguo #CancerResearch #GlobalHealth #PatientCare #Oncology
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
China’s CAR-T Cell Therapy: Leading a New Revolution in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma (MCL)
MCL
#CARTCellTherapy #MantleCellLymphoma #RelapsedMCL #RefractoryMCL #Hematology #MCL
Mantle Cell Lymphoma (MCL), a rare and complex subtype of non-Hodgkin’s lymphoma, exhibits both aggressive and indolent characteristics. Since MCL patients are usually diagnosed at an advanced stage, often with poor prognostic factors, traditional treatments such as chemotherapy and immunotherapy have brought survival benefits to some patients. However, most still face disease relapse or progression, particularly those with relapsed/refractory (r/r) MCL, where treatment poses significant challenges. For a long time, treatment options for MCL have been limited, making it difficult to achieve long-term remission or cure, highlighting the need for breakthroughs.
Chinese CAR-T Cell Therapy: Offering Hope for Relapsed/Refractory MCL With the rapid development of biotherapeutics, Chinese CAR-T cell therapy has emerged as a breakthrough innovation in lymphoma treatment. Since the approval of the world’s first CAR-T product in 2017, China has made significant progress in CAR-T research and application, especially in treating r/r MCL, where CAR-T therapy has shown excellent efficacy. CAR-T therapy not only significantly improves patient remission rates but also offers new survival opportunities for high-risk patients with poor prognoses.
Efficacy: In recent years, multiple international and Chinese clinical studies have confirmed the efficacy of CAR-T cell therapy in patients with relapsed/refractory MCL. Clinical data from China have also demonstrated outstanding results. In August 2024, the Chinese CAR-T product Relmacabtagene Autoleucel, a CD19-targeted CAR-T cell therapy, was approved for its third indication, treating adult patients with relapsed/refractory MCL (r/r MCL). Clinical data showed that Relmacabtagene Autoleucel achieved an overall response rate of 81.4%, with a complete response rate of 67.8%. The median progression-free survival (PFS) was 13 months, and the median overall survival (OS) was 19.5 months. These data further prove that Chinese CAR-T cell therapy not only has high efficacy in r/r MCL patients but also provides lasting survival benefits.
Side Effect Management: Despite its remarkable efficacy, CAR-T therapy is associated with certain side effects, such as cytokine release syndrome (CRS) and neurotoxicity (NT). However, with the continuous optimization of treatment technologies and accumulated experience in China, the incidence of side effects has been effectively controlled. In treating relapsed/refractory MCL patients, Chinese medical teams have been able to limit the occurrence of grade ≥3 CRS and NT to 6.8% in clinical practice. This lower toxicity makes CAR-T therapy safer in clinical applications, offering a new option for patients who cannot tolerate traditional treatments. Particularly for those who are resistant to Bruton’s tyrosine kinase inhibitors (BTKi) or ineligible for autologous hematopoietic stem cell transplantation, Chinese CAR-T therapy provides a gentler and effective treatment option.
Indications: The following groups of patients can benefit from Chinese CAR-T cell therapy:
-
Patients with relapsed/refractory MCL (r/r MCL)
-
MCL patients who do not respond to conventional treatments
-
Patients with poor prognostic factors (TP53 mutation, Ki67≥30%, blastoid MCL, pleomorphic MCL, POD24)
-
Patients previously exposed to BTKi or resistant/relapsed/refractory MCL
-
High-risk patients unsuitable for transplantation who cannot achieve good remission
Conclusion: With the widespread application of Chinese CAR-T therapy globally, more MCL patients, both domestic and international, are able to achieve deep remission and long-term survival. This not only marks a significant advancement in China’s hematological cancer treatment but also signifies that Chinese CAR-T cell therapy is leading a new transformation in the treatment of relapsed/refractory lymphoma worldwide.
🎉🎉To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#CancerTreatment #Immunotherapy #CancerResearch #Chinesemedicalbreakthrough #LymphomaTreatment #Oncology #Biotherapy #CancerInnovation
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
China’s BCMA CAR-T Therapy Offers Last Hope for Relapsed Multiple Myeloma Patients
### China’s BCMA CAR-T Therapy Offers Last Hope for Relapsed Multiple Myeloma Patients
CAR-T Therapy
Multiple myeloma remains a difficult-to-cure disease, and every year, countless patients around the world face this devastating diagnosis. While treatment options have improved in recent years, and patients’ survival times have extended, drug resistance remains a significant challenge. For patients who have experienced multiple relapses and are resistant to various treatments, the future can seem bleak. Fortunately, with the emergence of **BCMA CAR-T cell therapy**, a new ray of hope is illuminating the path for these patients.
This is the story we’re sharing today, about a 76-year-old female patient who regained control of her life through CAR-T therapy.
#### The First Encounter with the Disease
In 2020, this Chinese 76-year-old woman noticed a decline in appetite and a rapid weight loss, accompanied by persistent rib pain. She had no idea that these symptoms were early signs of multiple myeloma. After several medical tests, her Chinese doctors confirmed the diagnosis: 31% of her bone marrow cells were plasma cells, her M-protein levels reached 85.7 g/L, and calcium levels in her blood were abnormally high. Multiple bones throughout her body also showed signs of significant damage.
The diagnosis left the patient shocked and confused. Multiple myeloma wasn’t her first health challenge; she also had a history of Parkinson’s disease. However, she remained hopeful, believing that with the right treatment, her condition could be controlled. But fate had other plans.
#### The Struggle and Relapse
At the beginning of 2023, the patient’s condition relapsed rapidly. Due to a prolonged lack of regular treatment, her disease worsened, and she became resistant to many standard therapies. After extensive tests, her medical team discovered that she had a high-risk mSMART 3.0 profile, with genetic abnormalities including 1q21 amplification and a t(4;14) translocation, making her prognosis extremely poor. She was now considered a “triple-refractory” patient, resistant to three main treatment categories.
Faced with this complex and challenging situation, the Chinese doctors didn’t give up. After multiple discussions and research, they recommended a cutting-edge therapy — **BCMA CAR-T cell therapy**. This treatment involves modifying the patient’s immune cells to target and destroy cancer cells. However, to undergo this advanced therapy, the patient first needed to undergo **bridging treatment** to reduce the tumor burden in her body.
#### Bridging Treatment: A Turning Point
To prepare for CAR-T therapy, the Chinese doctors initially prescribed the **DKD regimen**, a combination therapy intended to quickly reduce the cancer cell load. However, the first treatment cycle didn’t bring significant improvement, and her free light chain levels remained high. Both the patient and her family felt disappointed, but the Chinese doctors acted quickly, switching to the **KAD regimen**, which included **liposomal doxorubicin** to further enhance the treatment’s effectiveness.
This adjustment brought immediate results. After a few weeks, her free light chain levels began to drop, and her condition showed partial remission (PR). This meant she was finally ready for CAR-T cell therapy.
#### The Miracle of CAR-T Therapy
CAR-T therapy is a breakthrough technology where the patient’s immune cells are extracted, genetically modified to recognize and destroy cancer cells, and then reintroduced into the body. These engineered cells act like precision-guided weapons, specifically targeting her cancer cells.
The patient responded positively to the treatment. Within just a few weeks, her condition was significantly controlled, with results showing a very good partial response (VGPR). For such a complex case of relapsed and refractory disease, this was a major success.
#### The Significance of the Story
This patient’s story highlights China’s latest advancements in the treatment of multiple myeloma. The use of **carfilzomib-based bridging therapy** paved the way for CAR-T therapy, successfully giving a patient with a poor prognosis a new chance at life. For those facing the dual challenges of drug resistance and relapse, **BCMA CAR-T therapy** offers not just a new treatment option, but a lifeline.
The product that has renewed hope for this 76-year-old Chinese woman is a BCMA-targeted CAR-T therapy that has already been launched in China. China is changing the fate of patients worldwide through advanced cancer treatments. Notably, in the field of CAR-T technology related to hematologic tumors and multiple myeloma, two BCMA CAR-T products have been approved in China. Especially commendable is Reindeer Bio’s independently developed fully human BCMA product, FUCASO, which has achieved an astonishing complete remission (CR) rate of 82.4%, the highest among all globally approved products. An increasing number of foreign multiple myeloma patients are now seeking treatment in China to access better therapies at more affordable prices. As China continues to develop cutting-edge medical therapies, aggressive treatments like CAR-T undoubtedly provide new hope for the future of multiple myeloma treatment.
Follow us for more stories of medical innovation and to witness how miracles of life are born in China!
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: +8613717959070
Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#MultipleMyeloma #CancerTreatment #CAR_TTherapy #BCMACAR_T #CancerSurvivor #Immunotherapy #ChinaMedicalInnovation #CancerResearch #CancerHope #MedicalBreakthrough #MyelomaAwareness #AdvancedCancerCare #RelapsedMyeloma #LifeSavingTreatment #PatientSuccessStory #CancerCare #GlobalHealth #CAR_TSuccess #Oncology #CancerSupport
#ChineseMedical #ChinaHealthcare #MedicalCareInChina #HealthcareInChina · #USMedical #USHealthcare #HealthcareInUSA #AmericanMedical #MedicalCareInUSA #USAHealth #AmericanHealthcare
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Why More and More Foreigners Are Choosing China for CAR-T Cell Therapy
**Why More and More Foreigners Are Choosing China for CAR-T Cell Therapy**
CAR-T
In recent years, China’s advancements in cell therapy, particularly CAR-T therapy, have been remarkable, attracting numerous international patients seeking treatment. With its cutting-edge technology, reasonable costs, and outstanding efficacy, China has become a preferred destination for cancer patients worldwide. Today, we will explore why an increasing number of foreign patients choose to come to China for cell therapy.
**The Rise of CAR-T Therapy: China’s Advantages**
First, CAR-T therapy is a personalized immunotherapy that specifically targets blood-related cancers such as lymphoma, multiple myeloma, and leukemia. By engineering a patient’s own T-cells to recognize and attack cancer cells, CAR-T therapy has shown significant efficacy, especially in patients with advanced cancer.
China’s advantages in cell therapy can be summarized into three key points:
-
**Technological Expertise**: China has accumulated extensive experience in CAR-T therapy, particularly in top hospitals in major cities like Shanghai and Beijing. These institutions boast world-class medical teams and advanced treatment systems, providing international patients with high-quality treatment plans that ensure global leading outcomes.
-
**Affordable Costs**: While CAR-T therapy can cost millions of dollars in countries like the U.S. and Europe, the treatment in China is much more affordable, usually about one-seventh to one-tenth of the cost in the U.S. This affordability makes China an attractive option for many international patients.
-
**Shorter Waiting Times**: In Western countries, patients often wait several months for CAR-T therapy, whereas in China, many hospitals can complete the entire process — from diagnosis to cell infusion — in just a few weeks. This is crucial for patients with urgent medical needs.
**Real-Life Cases: Why Foreign Patients Choose China**
Several real-life cases clearly demonstrate why international patients are increasingly seeking treatment in China.
– **Ethan from Singapore**
Ethan had been battling cancer for nearly ten years, trying various treatments globally with little success. Eventually, he decided to seek treatment in China. After a thorough evaluation at Jiahui International Hospital in Shanghai, Ethan received a personalized CAR-T therapy plan. Within just four weeks, his cancer cells had significantly decreased, and his health began to improve, along with his weight. Ethan remarked, “The treatment in China is not only effective but also much more affordable than in Singapore.”
– **A Russian Patient’s Story**
Borzinkov, a 70-year-old patient with high-risk advanced multiple myeloma, had experienced multiple treatment failures before learning about China’s CAR-T therapy. He traveled to China for treatment, successfully completed cell collection, and received CAR-T infusion. Just 13 days later, he was discharged, and his follow-up results have been very promising. He chose China not only for the lower costs but also because of the shorter waiting time.
These cases illustrate that international patients in China can receive high-quality, effective treatment at more affordable rates and with faster recovery times. So far, patients from countries like Russia, Singapore, Malaysia, and others have undergone CAR-T therapy in China and achieved significant results, with many experiencing complete remission within months, with no signs of cancer after treatment.
**China’s Leading Position and Future Prospects**
China has already established itself as a global leader in CAR-T therapy, accounting for over 50% of the world’s clinical trials in this field. Chinese researchers and doctors excel not only in the basic research and clinical applications of CAR-T therapy but also in managing side effects such as CRS and neurotoxicity.
In cities like Shanghai, Wuhan, and Beijing, doctors provide cutting-edge treatment to international patients daily, consistently delivering excellent outcomes. As China’s medical system continues to advance, more and more international patients are choosing China as their destination for treatment.
**Conclusion**
The reasons why foreign patients are choosing China for cell therapy are clear: China excels in technology, offers reasonable treatment costs, and delivers outstanding results. As the world becomes more aware of the progress in China’s healthcare system, more patients will seek advanced medical care in China. In particular, China’s breakthroughs in cell therapy will continue to attract cancer patients from across the globe.
🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can contact us for preliminary evaluation!
WhatsApp: +8613717959070
Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#CARtherapy #CellTherapy #CancerTreatment #Immunotherapy #HealthcareInnovation #MedicalTourism #ChinaHealthcare #CancerSurvivor #PatientStories #MedicalAdvancements #AffordableHealthcare #PersonalizedMedicine #GlobalHealth #HealthJourney #Oncology #CAR-T
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Chinese ADC Drug Targeting B7-H3 Approved for Clinical Trials!
Chinese ADC Drug Targeting B7-H3 Approved for Clinical Trials!
ADC